United States, September 16, 2026
Mighty Therapeutics has announced a partnership with the POLG Foundation to develop a novel preclinical disease model designed to advance research into POLG-related mitochondrial disorders and Parkinson’s disease. The collaboration aims to address an important challenge in mitochondrial medicine by creating an experimental model that can help researchers better understand disease mechanisms and evaluate potential therapeutic approaches. POLG-related disorders are associated with pathogenic variants in the POLG gene, which encodes the catalytic subunit of mitochondrial DNA polymerase gamma, an enzyme essential for maintaining mitochondrial DNA. The partnership brings together Mighty Therapeutics’ drug-development expertise and the POLG Foundation’s disease-focused knowledge to support development of a research model that could contribute to future therapeutic discovery.
New Model Targets POLG Mitochondrial Disorders
The POLG gene plays a critical role in mitochondrial biology because mitochondrial DNA must be accurately replicated and maintained for cells to produce energy efficiently. Pathogenic POLG variants can interfere with mitochondrial DNA maintenance and lead to a range of inherited mitochondrial diseases. Depending on the specific genetic variant and disease mechanism, affected individuals can develop neurological, muscular, and multisystem manifestations. Mighty Therapeutics and the POLG Foundation are seeking to develop a novel preclinical model that more effectively reproduces important biological characteristics associated with POLG disease. Such models can provide researchers with controlled systems for studying how mitochondrial dysfunction develops and progresses. They can also support the evaluation of candidate treatments before those therapies advance toward human clinical studies. The collaboration is particularly relevant because mitochondrial disorders can involve complex disease mechanisms that are difficult to reproduce using conventional laboratory systems. A disease model that captures relevant POLG-associated mitochondrial dysfunction could therefore provide researchers with additional opportunities to investigate mitochondrial DNA instability, cellular energy production, neuronal dysfunction, and disease progression.
Connecting POLG Biology With Parkinson’s Research
The partnership also includes an important focus on Parkinson’s disease, a neurodegenerative disorder in which mitochondrial dysfunction has been an area of extensive scientific investigation. Mitochondria provide neurons with the energy required for normal cellular activity, and disruptions in mitochondrial function can affect neuronal survival and cellular signaling. By examining POLG-associated mitochondrial dysfunction in a preclinical system relevant to neurological disease, researchers may be able to investigate biological pathways connecting mitochondrial DNA maintenance and neurodegeneration. The model could help scientists explore how changes in mitochondrial biology influence neuronal health and potentially identify molecular pathways that could be targeted therapeutically. However, a preclinical model is a research tool and does not itself demonstrate that a treatment will be effective in patients. Further laboratory validation and eventual clinical studies would be necessary to determine whether discoveries made using the model translate into meaningful therapeutic benefits.
Advertisement
Supporting Future Therapeutic Development
For biopharmaceutical research, improved disease models can play an important role in identifying potential drug targets and evaluating experimental compounds. Researchers can use preclinical models to investigate disease mechanisms, characterize biological responses, establish proof-of-concept, and prioritize therapeutic candidates for additional development. The Mighty Therapeutics and POLG Foundation collaboration is intended to create such a platform for POLG-related mitochondrial disease research. The organizations will work toward developing and characterizing the model so that it can be used for drug discovery, target validation, mechanism-of-action studies, and preclinical therapeutic evaluation.
The initiative also highlights the growing importance of partnerships between biotechnology organizations and disease-focused foundations. Patient and research foundations can provide specialized knowledge about disease biology and unmet needs, while biotechnology companies can contribute capabilities in experimental model development and therapeutic research. Combining these areas of expertise can help accelerate the creation of research resources for rare and complex disorders. The development of a novel POLG preclinical model could ultimately provide researchers with a valuable platform for studying mitochondrial disease and neurodegeneration. By connecting POLG biology with Parkinson’s disease research, the collaboration may help expand understanding of mitochondrial mechanisms and support the identification of potential therapeutic strategies. As the model advances through development and validation, researchers will be able to determine its utility for investigating disease pathways and evaluating prospective treatments.
Source: Mighty Therapeutics press release
